Aclaris Therapeutics Stock News

Allegheny Technologies (NYSE:ATI) is set to release its earnings data before the market opens on Tuesday, August 4th. Analysts expect Allegheny Technologies to post earnings of ($0.11) per share for t

Renting is likely to be the better option when seeking a holiday home than missing out on the income and growth of a substantial share portfolio.

Two Sigma Advisers LP lessened its position in shares of Aclaris Therapeutics Inc (NASDAQ:ACRS) by 40.1% in the first quarter, according to the company in its most recent 13F filing with the Securitie

Aclaris (ACRS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Aclaris Therapeutics, Inc. (ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for immuno-inflammatory diseases, today announced that it has submitted an

Equities analysts predict that Aclaris Therapeutics Inc (NASDAQ:ACRS) will post ($0.34) earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for Aclaris Therap

At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).

Aclaris Therapeutics (NASDAQ:ACRS) and Aytu Bioscience (NASDAQ:AYTU) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strengt

Aclaris Therapeutics Inc (NASDAQ:ACRS)’s share price dropped 4.3% during trading on Friday . The company traded as low as $1.55 and last traded at $1.57, approximately 8,317 shares changed hands dur

Aclaris (ACRS) announces that it supports an IND application to evaluate its oral investigational MK2 inhibitor compound, ATI-450, in hospitalized patients with COVID-19.

Looking into the current session, Aclaris Therapeutics Inc. (NASDAQ: ACRS) shares are trading at $1.76, after a 18.92% increase. Moreover, over the past month, the stock spiked by 37.50%, but in the p

FDA Allows IND to Study ATI-450 in Hospitalized Patients with COVID-19Aclaris Supports Investigator-Initiated Clinical Trial Sponsored by the University of Kansas Medical.

Shares of micro-cap biopharma Aclaris Therapeutics Inc (NASDAQ: ACRS) were rallying Wednesday after the FDA gave its blessing for the company's investigational new drug...

Everything we know about the PS5 price so far

WAYNE, Pa., June 03, 2020 -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates for.